Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies

S. Monfardini, R. Sorio, G. H. Boes, S. Kaye, D. Serraino

Research output: Contribution to journalArticle

Abstract

Background. This study aimed to determine the extent to which elderly patients (≥65 years) currently are being entered in Phase II single-agent studies, and if advanced age is associated with increased toxicity. Methods. This analysis was based on the age distribution of 2344 patients with various solid tumors entering 16 Phase II EORTC single-agent trials from January 1983 to February 1992. Results. Of the study group, 22% were 65 years or older and 8% were 79 years or older. Delay in dose administration and dose reduction were significantly higher for elderly patients compared with younger patients (P <0.05). When adjusting for previous chemotherapy pretreatment, no difference between elderly and nonelderly patients was noted in the frequency of grade 3 and 4 hematological toxicity, nausea, vomiting, and diarrhea. A significant higher frequency of episodes of severe oral toxicity (P <0.05) and alopecia were observed for elderly patients, but a higher proportion (P <0.05) of elderly patients received drugs for which stomatitis was an established side effect. No significant difference in the frequency of complete plus partial responses was observed between older and younger patients (9% versus 7%). Treatment discontinuation significantly increased with age, ranging from 24% for those younger than 50 years to 33% among elderly patients (x for trend = 12.83, P <0.001). There was not evidence that excess toxicity was an obstacle to treatment continuation for elderly patients, whereas treatment discontinuation did occur for the older age group more frequently because of loss to follow-up and treatment refusal. Conclusion. Selected elderly patients can and should enter new-drug- development protocols without an increased risk of more severe or frequent side effects. A priori exclusion based on an arbitrary chronologic age limit no longer should occur.

Original languageEnglish
Pages (from-to)333-338
Number of pages6
JournalCancer
Volume76
Issue number2
DOIs
Publication statusPublished - 1995

Fingerprint

Organizations
Research
Pharmaceutical Preparations
Neoplasms
Therapeutics
Treatment Refusal
Stomatitis
Alopecia
Age Distribution
Nausea
Vomiting
Diarrhea
Age Groups
Drug Therapy

Keywords

  • chemotherapy in the elderly
  • drug toxicity in the elderly
  • entry of elderly in Phase II
  • new drug development in elderly patients
  • Phase II studies in the elderly

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. / Monfardini, S.; Sorio, R.; Boes, G. H.; Kaye, S.; Serraino, D.

In: Cancer, Vol. 76, No. 2, 1995, p. 333-338.

Research output: Contribution to journalArticle

@article{a258798ccf294f2fb711b124bf423e68,
title = "Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies",
abstract = "Background. This study aimed to determine the extent to which elderly patients (≥65 years) currently are being entered in Phase II single-agent studies, and if advanced age is associated with increased toxicity. Methods. This analysis was based on the age distribution of 2344 patients with various solid tumors entering 16 Phase II EORTC single-agent trials from January 1983 to February 1992. Results. Of the study group, 22{\%} were 65 years or older and 8{\%} were 79 years or older. Delay in dose administration and dose reduction were significantly higher for elderly patients compared with younger patients (P <0.05). When adjusting for previous chemotherapy pretreatment, no difference between elderly and nonelderly patients was noted in the frequency of grade 3 and 4 hematological toxicity, nausea, vomiting, and diarrhea. A significant higher frequency of episodes of severe oral toxicity (P <0.05) and alopecia were observed for elderly patients, but a higher proportion (P <0.05) of elderly patients received drugs for which stomatitis was an established side effect. No significant difference in the frequency of complete plus partial responses was observed between older and younger patients (9{\%} versus 7{\%}). Treatment discontinuation significantly increased with age, ranging from 24{\%} for those younger than 50 years to 33{\%} among elderly patients (x for trend = 12.83, P <0.001). There was not evidence that excess toxicity was an obstacle to treatment continuation for elderly patients, whereas treatment discontinuation did occur for the older age group more frequently because of loss to follow-up and treatment refusal. Conclusion. Selected elderly patients can and should enter new-drug- development protocols without an increased risk of more severe or frequent side effects. A priori exclusion based on an arbitrary chronologic age limit no longer should occur.",
keywords = "chemotherapy in the elderly, drug toxicity in the elderly, entry of elderly in Phase II, new drug development in elderly patients, Phase II studies in the elderly",
author = "S. Monfardini and R. Sorio and Boes, {G. H.} and S. Kaye and D. Serraino",
year = "1995",
doi = "10.1002/1097-0142(19950715)76:2<333::AID-CNCR2820760226>3.0.CO;2-I",
language = "English",
volume = "76",
pages = "333--338",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies

AU - Monfardini, S.

AU - Sorio, R.

AU - Boes, G. H.

AU - Kaye, S.

AU - Serraino, D.

PY - 1995

Y1 - 1995

N2 - Background. This study aimed to determine the extent to which elderly patients (≥65 years) currently are being entered in Phase II single-agent studies, and if advanced age is associated with increased toxicity. Methods. This analysis was based on the age distribution of 2344 patients with various solid tumors entering 16 Phase II EORTC single-agent trials from January 1983 to February 1992. Results. Of the study group, 22% were 65 years or older and 8% were 79 years or older. Delay in dose administration and dose reduction were significantly higher for elderly patients compared with younger patients (P <0.05). When adjusting for previous chemotherapy pretreatment, no difference between elderly and nonelderly patients was noted in the frequency of grade 3 and 4 hematological toxicity, nausea, vomiting, and diarrhea. A significant higher frequency of episodes of severe oral toxicity (P <0.05) and alopecia were observed for elderly patients, but a higher proportion (P <0.05) of elderly patients received drugs for which stomatitis was an established side effect. No significant difference in the frequency of complete plus partial responses was observed between older and younger patients (9% versus 7%). Treatment discontinuation significantly increased with age, ranging from 24% for those younger than 50 years to 33% among elderly patients (x for trend = 12.83, P <0.001). There was not evidence that excess toxicity was an obstacle to treatment continuation for elderly patients, whereas treatment discontinuation did occur for the older age group more frequently because of loss to follow-up and treatment refusal. Conclusion. Selected elderly patients can and should enter new-drug- development protocols without an increased risk of more severe or frequent side effects. A priori exclusion based on an arbitrary chronologic age limit no longer should occur.

AB - Background. This study aimed to determine the extent to which elderly patients (≥65 years) currently are being entered in Phase II single-agent studies, and if advanced age is associated with increased toxicity. Methods. This analysis was based on the age distribution of 2344 patients with various solid tumors entering 16 Phase II EORTC single-agent trials from January 1983 to February 1992. Results. Of the study group, 22% were 65 years or older and 8% were 79 years or older. Delay in dose administration and dose reduction were significantly higher for elderly patients compared with younger patients (P <0.05). When adjusting for previous chemotherapy pretreatment, no difference between elderly and nonelderly patients was noted in the frequency of grade 3 and 4 hematological toxicity, nausea, vomiting, and diarrhea. A significant higher frequency of episodes of severe oral toxicity (P <0.05) and alopecia were observed for elderly patients, but a higher proportion (P <0.05) of elderly patients received drugs for which stomatitis was an established side effect. No significant difference in the frequency of complete plus partial responses was observed between older and younger patients (9% versus 7%). Treatment discontinuation significantly increased with age, ranging from 24% for those younger than 50 years to 33% among elderly patients (x for trend = 12.83, P <0.001). There was not evidence that excess toxicity was an obstacle to treatment continuation for elderly patients, whereas treatment discontinuation did occur for the older age group more frequently because of loss to follow-up and treatment refusal. Conclusion. Selected elderly patients can and should enter new-drug- development protocols without an increased risk of more severe or frequent side effects. A priori exclusion based on an arbitrary chronologic age limit no longer should occur.

KW - chemotherapy in the elderly

KW - drug toxicity in the elderly

KW - entry of elderly in Phase II

KW - new drug development in elderly patients

KW - Phase II studies in the elderly

UR - http://www.scopus.com/inward/record.url?scp=0029009209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029009209&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19950715)76:2<333::AID-CNCR2820760226>3.0.CO;2-I

DO - 10.1002/1097-0142(19950715)76:2<333::AID-CNCR2820760226>3.0.CO;2-I

M3 - Article

C2 - 8625111

AN - SCOPUS:0029009209

VL - 76

SP - 333

EP - 338

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -